← Leaderboards
Robert P Bowser
University Of Pittsburgh At Pittsburgh
$16,513,448
Attributed
$59,967,528
Total exposure
13
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $20.2M · FY2005–25$25M$18.8M$12.5M$6.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$59,967,528 · 13
By mechanism
OT2$51,203,440 · 1
R01$3,938,873 · 3
R21$1,236,340 · 3
R42$1,121,400 · 1
RC1$976,706 · 1
R56$687,087 · 1
Top collaborators
- Merit E Cudkowicz3 shared
- Matthew Harms3 shared
- Brent T Harris3 shared
- Hemali Phatnani3 shared
- Frank A Provenzano3 shared
- Neil Alan Shneider3 shared
- David Medina1 shared
- Sarah E Stabenfeldt1 shared
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Christopher James Donnelly$6,743,962
Others in their field
Top investigators on “Amyotrophic Lateral Sclerosis”
- Merit E Cudkowicz · Massachusetts General Hospital$54,029,758
- James Dale Berry · Brigham And Women'S Hospital$37,291,450
- Sabrina Paganoni · Massachusetts General Hospital$36,168,406
- Suma Babu · Massachusetts General Hospital$36,168,406
- Jeffrey D Rothstein · Massachusetts General Hospital$22,909,620
- Teepu Siddique · University Of Chicago$22,641,778
Research focus
Amyotrophic Lateral SclerosisSamplingProteinsCerebrospinal FluidSymptomsSpinal CordClinical TrialsMonitorDiagnosticMotor NeuronsBaseTissuesEnzyme-Linked Immunosorbent AssayCollectionAntibodiesDiagnosisBloodMolecularBiomarkerFutureOnset Of IllnessClinical ResearchAdultDegenerative Disorder
Grant awards (35)
Access for All in ALS (ALL ALS) West Clinical Coordinating Center$20,235,572
OT2 · FY2025 · NS · contact PI
Access for All in ALS (ALL ALS) West Clinical Coordinating Center$14,234,367
OT2 · FY2024 · NS · contact PI
Access for All in ALS (ALL ALS) West Clinical Coordinating Center$16,733,501
OT2 · FY2023 · NS · contact PI
Linking TBI secondary injuries to FTLD- and ALS-like neurodegeneration$157,000
R03 · FY2021 · NS
Novel knock-in mouse models of ALS and myopathy-linked Matrin 3 mutations$435,387
R21 · FY2020 · NS
Commercialization of a Diagnostic test for amyotrophic lateral sclerosis (ALS)$137,106
R42 · FY2015 · NS · contact PI
Commercialization of a Diagnostic test for amyotrophic lateral sclerosis (ALS)$5,000
R42 · FY2015 · NS · contact PI
Commercialization of a Diagnostic test for amyotrophic lateral sclerosis (ALS)$813,592
R42 · FY2014 · NS · contact PI
Peptide and Protein Biomarkers for Amyotrophic Lateral Sclerosis (ALS)$687,087
R56 · FY2014 · NS · contact PI
Peptide and Protein Biomarkers for Amyotrophic Lateral Sclerosis (ALS)$313,898
R01 · FY2013 · NS · contact PI
Commercialization of a Diagnostic test for amyotrophic lateral sclerosis (ALS)$165,702
R42 · FY2013 · NS · contact PI
Peptide and Protein Biomarkers for Amyotrophic Lateral Sclerosis (ALS)$325,283
R01 · FY2012 · NS · contact PI
Peptide and Protein Biomarkers for Amyotrophic Lateral Sclerosis (ALS)$260,000
R01 · FY2011 · NS · contact PI
Peptide and Protein Biomarkers for Amyotrophic Lateral Sclerosis (ALS)$64,778
R01 · FY2011 · NS · contact PI
Multi-Center Validation of Biomarkers for Motor Neuron Disease$385,307
RC1 · FY2010 · NS · contact PI
Peptide and Protein Biomarkers for Amyotrophic Lateral Sclerosis (ALS)$328,093
R01 · FY2010 · NS · contact PI
Cellular Approaches to Tissue Engineering and Regeneration$266,942
T32 · FY2010 · EB · contact PI
Multi-Center Validation of Biomarkers for Motor Neuron Disease$100,000
RC1 · FY2010 · NS · contact PI
Multi-Center Validation of Biomarkers for Motor Neuron Disease$491,399
RC1 · FY2009 · NS · contact PI
Peptide and Protein Biomarkers for Amyotrophic Lateral Sclerosis (ALS)$331,406
R01 · FY2009 · NS · contact PI
Cellular Approaches to Tissue Engineering and Regeneration$267,240
T32 · FY2009 · EB · contact PI
Transcriptional Responses in Neurodegenerative Diseases$247,106
R01 · FY2007 · NS · contact PI
Transcriptional Responses in Neurodegenerative Diseases$254,486
R01 · FY2006 · NS · contact PI
Proteomic profiling of CSF during SIV infection$212,166
R21 · FY2006 · MH · contact PI
Transcriptional Responses in Neurodegenerative Diseases$260,611
R01 · FY2005 · NS
ALS biomarkers in the cerebrospinal fluid$222,750
R21 · FY2005 · ES
Proteomic profiling of CSF during SIV infection$180,307
R21 · FY2005 · MH
NOVEL ANTIGEN IN DEVELOPING BRAIN AND ALZHEIMERS DISEASE$292,839
R01 · FY2004 · NS
Transcriptional Responses in Neurodegenerative Diseases$261,000
R01 · FY2004 · NS
ALS biomarkers in the cerebrospinal fluid$185,730
R21 · FY2004 · ES
NOVEL ANTIGEN IN DEVELOPING BRAIN AND ALZHEIMERS DISEASE$334,346
R01 · FY2003 · NS
NOVEL ANTIGEN IN DEVELOPING BRAIN AND ALZHEIMERS DISEASE$335,609
R01 · FY2002 · NS
NOVEL ANTIGEN IN DEVELOPING BRAIN AND ALZHEIMERS DISEASE$288,574
R01 · FY2001 · NS
NOVEL ANTIGEN IN DEVELOPING BRAIN AND ALZHEIMERS DISEASE$40,844
R01 · FY2001 · NS
NOVEL ANTIGEN IN DEVELOPING BRAIN AND ALZHEIMERS DISEASE$112,500
R29 · FY2000 · AG